SEC Form 4/A · accession 0002048588-26-000010
Beta Bionics, Inc. · BBNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Stephen Feider
Officer — Chief Financial Officer
Period of report
Jun 26, 2026
Accepted (ET)
Jul 2, 2026 · 6:44 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001674632
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 26, 2026 | M | 5,104 | $5.10 | A | 171,157 | D | |
| Common StockF3,F1 | Jun 26, 2026 | S | 5,104 | $17.0467 | D | 166,053 | D | |
| Common StockF1 | Jun 29, 2026 | M | 4,896 | $5.10 | A | 170,949 | D | |
| Common StockF4,F1 | Jun 29, 2026 | S | 4,896 | $17.0304 | D | 166,053 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F5 | $5.10 | Jun 26, 2026 | M | 5,104 | D | — | Sep 13, 2033 | Common Stock | 5,104 | 44,591 | D |
| Employee Stock Option (right to buy)F1,F5 | $5.10 | Jun 29, 2026 | M | 4,896 | D | — | Sep 13, 2033 | Common Stock | 4,896 | 39,695 | D |
Explanation of responses
- F1This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions.
- F2Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
- F3The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F5The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.